Short Interest in Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Declines By 12.2%
Amneal Pharmaceuticals, Inc. (NYSE:AMRX – Get Free Report) saw a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 3,180,000 shares, a decrease of 12.2% from the November 15th total of 3,620,000 shares. Approximately 5.8% of the shares of the company are sold short. Based on an average daily volume of 1,290,000 shares, the days-to-cover ratio is currently 2.5 days.
Amneal Pharmaceuticals Price Performance
NYSE AMRX traded up $0.19 on Friday, hitting $5.19. 3,185,458 shares of the company’s stock were exchanged, compared to its average volume of 1,135,681. The stock has a 50-day moving average of $4.25 and a 200-day moving average of $3.75. The company has a current ratio of 1.91, a quick ratio of 1.16 and a debt-to-equity ratio of 16.75. Amneal Pharmaceuticals has a 52 week low of $1.24 and a 52 week high of $5.24. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of 86.50 and a beta of 1.26.
Amneal Pharmaceuticals (NYSE:AMRX – Get Free Report) last released its earnings results on Tuesday, November 7th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.07. Amneal Pharmaceuticals had a return on equity of 109.82% and a net margin of 0.43%. The firm had revenue of $620.04 million during the quarter, compared to analysts’ expectations of $613.74 million. Analysts expect that Amneal Pharmaceuticals will post 0.49 earnings per share for the current year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the stock. Morgan Stanley grew its holdings in Amneal Pharmaceuticals by 935.8% during the 4th quarter. Morgan Stanley now owns 4,220,998 shares of the company’s stock worth $8,400,000 after acquiring an additional 3,813,489 shares during the period. Millennium Management LLC grew its stake in shares of Amneal Pharmaceuticals by 153.3% in the 4th quarter. Millennium Management LLC now owns 5,013,378 shares of the company’s stock valued at $9,977,000 after buying an additional 3,034,426 shares during the period. Norges Bank acquired a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at about $5,402,000. Rubric Capital Management LP acquired a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter valued at about $8,064,000. Finally, Vanguard Group Inc. grew its stake in shares of Amneal Pharmaceuticals by 10.8% in the 1st quarter. Vanguard Group Inc. now owns 12,830,372 shares of the company’s stock valued at $53,504,000 after buying an additional 1,255,477 shares during the period. 31.82% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
AMRX has been the topic of several research reports. Truist Financial upped their target price on Amneal Pharmaceuticals from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. StockNews.com assumed coverage on Amneal Pharmaceuticals in a research report on Monday, November 13th. They set a “buy” rating on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $4.80.
View Our Latest Report on Amneal Pharmaceuticals
Amneal Pharmaceuticals Company Profile (Get Free Report)
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Amneal Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Amneal Pharmaceuticals wasn’t on the list.
While Amneal Pharmaceuticals currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Original: MarketBeat News Feed: Short Interest in Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Declines By 12.2%